Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)

Condition(s): Hypertension
NCTId: NCT00871871

Official Title

A Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Evaluate the Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis in Obese Patients With Hypertension

Summary

This study will measure and compare changes in insulin production and sensitivity using the hyperglycemic clamp technique in obese patients with impaired glucose tolerance and hypertension treated with placebo, isosorbide mononitrate (ISMN) or hydrochlorothiazide (HCTZ).

Eligibility

Eligibility Criteria

Gender Minimum Age Maximum Age Healthy Volunteers?
Both 35 Years 75 Years False

Inclusion Criteria:

- Female participants must be post-menopausal

- Body Mass Index (BMI) of at least 29 kg/m^2

- Weight has been stable over the past 3 months

- Has never been treated for hypertension or is diagnosed with hypertension taking up to 2 anti-hypertensive medications

- Willing to stop hypertension treatment for 14 days prior to randomization and throughout the study

- Does not have a history of diabetes

- In good health with the exception of hypertension

- No history of abnormal heart rhythms

- Part I only: willing to comply with high potassium/low sodium diet for the duration of the study

- Willing to avoid strenuous physical activity during the study

- Nonsmoker and/or has not used nicotine for at least 3 months and agrees to refrain from use of tobacco-containing products throughout the study

- Agrees to refrain from consuming alcohol and caffeine during in-patient periods and to limit consumption at all other times during the study

- Agrees not to consume grapefruit, grapefruit products, and citrus, apple, and pineapple juices 2 weeks prior to administration of the first dose of study drug

Exclusion Criteria:

- History of any illness that may make their participation in the study unsafe or confuse the study results

- Taking spironolactone or eplerenone

- Cannot refrain from using any prescription or non-prescription drugs during the study

- On a weight loss program and is not in the maintenance phase

- Started a weight loss drug within 8 weeks of the first study visit

- Consumes excessive amounts of alcohol or caffeine

- Has had major surgery, donated or lost 1 unit of blood within 4 weeks of the first study visit

- History of multiple and/or severe allergies to drugs or food

- Is dehydrated

Interventions & Outcomes

Study Interventions & Types

Drug Intervention(s)

Comparator: Placebo to HCTZ - Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
Comparator: Placebo to ISMN - Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
Hydrochlorothiazide (HCTZ) - HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
Isosorbide mononitrate (ISMN) - ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period

Study Outcomes

Primary Outcome(s)

Timeframe: 90 -120 minutes post-dose
Measure: Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants Who Had Normal Glucose Tolerance (NGT)
Description: Steady state was defined as 90-120 minutes post-dose. NGT participants (FPG <100 mg/dL & 2 hour plasma glucose (PG) <140 mg/dL during a 75g oral glucose tolerance test (OGTT) at screening) were neither Impaired Glucose Tolerant (IGT) nor Impaired Fasting Glucose (IFG). IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. IFG was defined as FPG between 100 and 125 mg/dL at screening.
Safety Issue? No

Timeframe: 90 -120 minutes post-dose
Measure: Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Fasting Glucose (IFG)
Description: Steady state was defined as 90-120 minutes post-dose. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening.
Safety Issue? No

Timeframe: 90 -120 minutes post-dose
Measure: Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT)
Description: Steady state was defined as 90-120 minutes post-dose. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening.
Safety Issue? No

Timeframe: 90 -120 minutes post-dose
Measure: Part II: Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady-state
Description: Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes.
Safety Issue? No

Secondary Outcome(s)

Measure: Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Fasting Glucose (IFG)
Timeframe: 90 -120 minutes post-dose
Description: Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening.
Safety Issue? No

Measure: Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Glucose Tolerant (IGT)
Timeframe: 90 -120 minutes post-dose
Description: Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening.
Safety Issue? No

Measure: Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Normal Glucose Tolerant (NGT)
Timeframe: 90 -120 minutes post-dose
Description: Steady state was defined as 90-120 minutes post-dose. The ratio was the measure of the quantity of glucose disposed per unit of plasma insulin concentration (PIC). Approximate PIC was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals, time = 90, 100, 110, and 120 minutes. NGT participants (FPG <100 mg/dL & 2 hour PG <140 mg/dL during a 75g OGTT at screening) were neither IGT nor IFG at screening. IGT - defined as a 2 hour PG >= 140 and <= 199 mg/dL during a 75g OGTT at screening. IFG - defined as FPG between 100 and 125 mg/dL at screening.
Safety Issue? No

Unfortunately, there is no location information available.
Please check back again later or Search for a different study

Related Keywords & Studies

Conditions and Diseases with Related Research Studies

  1. Hypertension

Related Intervention Keywords

Related Hypertension Research

  1. 26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
  2. 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
  3. 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects
  4. 52-104 Week Off-therapy Second Extension to Study CSPP100A2365
  5. 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
  6. 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
  7. A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
  8. A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Diabetic and Hypertensive Filipinos
  9. A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome
  10. A Behavioral Intervention To Improve Hypertension Control In Veterans
  11. A Bengali Dietary Salt Study to Control Blood Pressure